Physician

Christopher F. Lobo, MD

According to 2025 Medicare claims, Christopher Lobo, MD (NPI: 1073571949) practices hematology/oncology in the Punta Gorda, FL market, with the plurality of this provider's patient population coming from Charlotte, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33980-2012.

Lobo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,334 traditional Medicare patients, billed 774,577 HCPCS/CPT codes, and received $10,057,420 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,156 prescription claims across 627 beneficiaries totaling $7,884,011 in drug costs, led by Revlimid (Lenalidomide). DME data shows 267 claims. Open Payments data shows 37 records totaling $876. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,573,734 to $7,884,011. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $17,389 to $3,550.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,305	621,764	$6,376,982
2016	2,366	717,349	$7,381,177
2017	2,599	858,638	$8,353,306
2018	2,443	849,327	$8,595,251
2019	2,642	883,471	$9,547,905
2020	1,934	749,547	$9,379,146
2021	2,170	614,073	$9,894,248
2022	2,202	541,247	$8,715,151
2023	2,367	683,756	$10,146,782
2024	2,334	774,577	$10,057,420

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	442	2,682	$2,573,734
2016	491	2,930	$3,876,468
2017	529	3,088	$4,746,546
2018	530	2,759	$6,358,624
2019	550	2,713	$6,230,071
2020	546	3,011	$7,375,046
2021	537	3,006	$8,646,566
2022	532	2,734	$8,090,261
2023	593	3,074	$6,893,420
2024	627	3,156	$7,884,011

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	70	384	$90,177
2016	74	409	$108,043
2017	64	198	$59,687
2018	54	182	$30,073
2019	50	183	$19,705
2020	N/R	162	$12,522
2021	42	212	$13,352
2022	40	200	$8,842
2023	46	267	$29,642
2024	57	267	$11,439

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,377	3,143	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	382	484	$13
96372	Injection of drug or substance under skin or into muscle	496	1,546	$10
36415	Insertion of needle into vein for collection of blood sample	1,720	4,729	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,656	4,919	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	110	2,968	$1,878,856
Pomalyst	Pomalidomide	42	1,176	$809,545
Xtandi	Enzalutamide	49	1,470	$695,385
Jakafi	Ruxolitinib Phosphate	37	1,110	$622,595
Erleada	Apalutamide	44	1,320	$609,979

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4152	Enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	N	N/R	14	$2,624
J8521	Capecitabine, oral, 500 mg	N	11	53	$2,186
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	29	$2,003
J8700	Temozolomide, oral, 5 mg	N	N/R	30	$1,613
J8999	Prescription drug, oral, chemotherapeutic, nos	N	12	28	$1,156

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	37	$876	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher F. Lobo, MD?

Tedicare shows public-source Medicare data for Christopher F. Lobo, MD (NPI 1073571949), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher F. Lobo, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher F. Lobo, MD?

Christopher F. Lobo, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Christopher F. Lobo, MD have Open Payments data?

Christopher F. Lobo, MD has 37 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.